Smithkline Beecham Corporation

Proximagen Limited

Glaxo Group Limited

Peptinnovate Limited

Andrew Lightfoot

Roger Edward Markwell

Neil David Pearson

David Thomas Davies

Kevin Dinnell

Ian Thomson Forbes

Graham Elgin Jones

Howard Robert Marshall

Andrew H Payne

Andrew Derrick Gribble

Geoffrey Stemp

Michael S Hadley

Gregor James MacDonald

Vincenzo Garzya

Graham Walker

Anthony Robert Milnes Coates

Peter Tormay

Gillian Elizabeth Lunniss

Susan Roomans

David Dean

Gillian Elizabeth Luniss

Peptides from the polypeptide chaperonin 60.1, and their use in medicine for the treatment of inflammatory conditions are described.

Peptides from chaperonin 60.1

Compounds are disclosed which modulate the &#x3b1;7 nicotinic acetyl choline receptor (nAChR), having the formula (I) wherein the variables are as specified in the description and claims.

Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or alzheimer'S disease

This invention relates to modulation of the &#x3b1;7 nicotinic acetylcholine receptor (nAChR) by a compound of formula (I): or a pharmaceutically acceptable salt thereof.

Indole and azaindole modulators of the alpha 7 nachr

The present invention relates to modulation of the &#x3b1;7 nicotinic acetylcholine receptor (nAChR) by a compound of List A or a salt thereof, which may be represented, but is not limited to the compound N-[(2-Trifluoromethyl-1H-indol-5-yl)methyl]-2-(trifluoromethyl)-5-pyrimidinecarboxamide.

Indoles as modulators of nicotinic acetylcholine receptor subtype alpha-7

This invention relates to modulation of the &#x3b1;7 nicotinic acetylcholine receptor (nAChR) by a compound of formula (I) or a salt thereof 

Indole modulators of the alpha 7 nicotinic acetylcholine receptor

Aminopiperidine derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly in man 

Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity

The invention provides compounds of the formula 

2,3,4,5-tetrahydro-1H-3-benzazepines and their medical use

The invention provides compounds of formula (I): wherein: Rand Rindependently represent various substituents; Rand Rindependently represent H, F, Cl, Br, Calkyl, Calkoxy, OH, CN, or NO; B represents a sulfur atom or a &#x2014;CH-group; t represents 3 or 4; and A represents an optionally substituted 5- or 6-membered aromatic heterocyclic ring, or an optionally substituted bicyclic heterocyclic ring system in which at least the ring bound to the group B in Formula (I) is aromatic; or a salt thereof. Preferably, A is selected from one of the groups (i), (ii) or (iii): wherein Xand Xare independently N or CR, and Xis NR, O or S; Yand Yare independently N or CR, and Yis NR, O or S; Zis NR, O or S, and Zand Zare independently N or CR; R, R, and Rare as herein defined, and Ris H, a halogen atom, OH, cyano, nitro, Calkyl, Calkoxy, Calkylenedioxy, Calkanoyl, or Calkylsulfonyl, an optionally substituted 3-, 4-, 5- or 6-membered cycloalkyl ring, or a group of the formula (a), (b), (c) or (d) as defined by the formulas (a), (b), (c) or (d). The compounds are modulators of dopamine Dreceptors and have potential in the treatment of psychotic conditions (e.g. schizophrenia) or substance abuse.

Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents)

The invention provides compounds of formula (I): wherein The compounds are useful in therapy, in particular as antipsychotic agents.

Sulfonamide derivatives as antipsychotic agents

Aminopiperidine derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly in man.

Growing community of inventors

Harlow, United Kingdom

Andrew Lightfoot